s/hubermanlabWEIGHT-LOSS DRUG•9h
14
votes
467
seen
Eli Lilly’s retatrutide reached 23% weight loss in people with type 2 diabetes
People with type 2 diabetes lost an average of 70.3 pounds on the highest dose of Eli Lilly’s retatrutide, with the biggest reported loss reaching 23% of body weight. That pushes the drug beyond the weight-loss range established by current GLP-1 treatments in a population also managing diabetes.
Triple pathway
Retatrutide targets GLP-1, GIP, and glucagon receptors instead of relying on the GLP-1 pathway alone. At the highest dose, more than half of participants no longer met the criteria for obesity, and nearly 40% reached a normal A1C. The New England Journal of Medicine published the phase 3 article on September 30, 2026.
Triple pathway
Retatrutide targets GLP-1, GIP, and glucagon receptors instead of relying on the GLP-1 pathway alone. At the highest dose, more than half of participants no longer met the criteria for obesity, and nearly 40% reached a normal A1C. The New England Journal of Medicine published the phase 3 article on September 30, 2026.
Timeline3
19h
Eli Lilly reported that its investigational triple agonist produced an average 70.3-pound weight loss at the highest dose.
18h
Eli Lilly reported that more than half of participants no longer had obesity and nearly 40% reached a normal A1C at the highest dose.
12h
The New England Journal of Medicine published a phase 3 article on retatrutide as a triple hormone-receptor agonist.
1 comment
9h